Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial

被引：36

作者：

Bruix, J. ^{[1
]}

Merle, P. ^{[2
]}

Granito, A. ^{[3
]}

Huang, Y. -H. ^{[4
,5
]}

Bodoky, G. ^{[6
]}

Yokosuka, O. ^{[7
]}

Rosmorduc, O. ^{[8
,9
]}

Breder, V. ^{[10
]}

Gerolami, R. ^{[11
]}

Masi, G. ^{[12
]}

Paul, J. Ross ^{[13
]}

Qin, S. ^{[14
]}

Song, T. ^{[15
]}

Bronowicki, J. -P. ^{[16
]}

Ollivier-Hourmand, I. ^{[17
]}

Kudo, M. ^{[18
]}

LeBerre, M. -A. ^{[19
]}

Baumhauer, A. ^{[20
]}

Meinhardt, G. ^{[21
]}

Han, G. ^{[22
]}

机构：

[1] Univ Barcelona, Hosp Clin, BCLC Grp, Liver Unit, Barcelona, Spain

[2] Grt Hosp Lyon Nord, Hepatol Unit, Lyon, France

[3] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Bologna, Italy

[4] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan

[5] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan

[6] St Laszlo Teaching Hosp, Budapest, Hungary

[7] Chiba Univ, Dept Gastroenterol & Nephrol, Chiba, Japan

[8] Hop La Pitie Salpetriere, Dept Hepatol, AP HP, Paris, France

[9] Univ Paris 06, Sorbonne Univ, Paris, France

[10] Russian Canc Res Ctr, Moscow, Russia

[11] Univ Aix Marseille 2, CHU Timone, Marseille, France

[12] Azienda Osped Univ Pisana, Pisa, Italy

[13] Kings Coll Hosp NHS Fdn Trust, London, England

[14] Nanjing Bayi Hosp, Chinese Peoples Liberat Army Canc Ctr, Nanjing, Jiangsu, Peoples R China

[15] Tianjin Med Univ, Canc Hosp, Tianjin, Peoples R China

[16] Univ Lorraine, CHU Nancy, INSERM 954, Nancy, France

[17] CHU, Serv Hepatogastroenterol, Caen, France

[18] Kindai Univ, Fac Med, Osaka, Japan

[19] Bayer HealthCare SAS, Loos, France

[20] Bayer Vital GmbH, Bayer Pharmaceut, Leverkusen, Germany

[21] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[22] Fourth Mil Med Univ, Affiliated Hosp 1, Xian, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw237.03

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：140 / +

页数：2

共 50 条

[1] Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial
Woerns, M. -A.
Finn, R. S.
Merle, P.
Granito, A.
Huang, Y. -H.
Bodoky, G.
Pracht, M.
Yokosuka, O.
Rosmorduc, O.
Gerolami, R.
Caparello, C.
Cabrera, R.
Chang, C.
Sun, W.
LeBerre, M. -A.
Baumhauer, A.
Meinhardt, G.
Galle, P.
Bruix, J.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 161 - 161
[2] Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
Finn, Richard S.
Merle, Philippe
Granito, Alessandro
Huang, Yi-Hsiang
Bodoky, Gyorgy
Pracht, Marc
Yokosuka, Osamu
Rosmorduc, Olivier
Gerolami, Rene
Caparello, Chiara
Cabrera, Roniel
Chang, Charissa
Sun, Weijing
Han, Guohong
Le Berre, Marie-Aude
Baumhauer, Annette
Meinhardt, Gerold
Bruix, Jordi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[3] Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
Bruix, J.
Merle, P.
Granito, A.
Huang, Y-H.
Bodoky, G.
Yokosuka, O.
Rosmorduc, O.
Breder, V.
Gerolami, R.
Masi, G.
Ross, P. J.
Qin, S.
Song, T.
Bronowicki, J-P.
Ollivier-Hourmand, I.
Kudo, M.
LeBerre, M-A.
Baumhauer, A.
Meinhardt, G.
Han, G.
ANNALS OF ONCOLOGY, 2016, 27
[4] RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
Bruix, Jordi
Finn, Richard S.
Kudo, Masatashi
Llovet, Josep M.
Qin, Shukui
Le Berre, Marie-Aude
Wagner, Andrea
Chang, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Jordi, Bruix
Philippe, Merle
Alessandro, Granito
Huang Yi-Hsiang
Gyorgy, Bodoky
Osamu, Yokosuka
Olivier, Rosmorduc
Valeriy, Breder
Rene, Gerolami
Gianluca, Masi
Ross, Paul J.
Qin Shukui
Song Tianqiang
Jean-Pierre, Bronowicki
Isabelle, Ollivier-Hourmand
Masatoshi, Kudo
Marie-Aude, LeBerre
Annette, Baumhauer
Gerold, Meinhardt
Han Guohong
ANNALS OF ONCOLOGY, 2017, 28
[6] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Llovet, J.
Ricci, S.
Mazzaferro, V.
Hilgard, P.
Raoul, J.
Zeuzem, S.
Poulin-Costello, M.
Moscovici, M.
Voliotis, D.
Bruix, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Tumor biomarkers and regorafenib (REG) efficacy in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
Teufel, Michael
Seidel, Henrik
Kochert, Karl
Meinhardt, Gerold
Finn, Richard S.
Llovet, Josep M.
Bruix, Jordi
HEPATOLOGY, 2017, 66 : 756A - 757A
[8] Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)
Koechert, K.
Meinhardt, G.
Bruix, J.
Teufel, M.
ANNALS OF ONCOLOGY, 2018, 29 : 236 - 236
[9] Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib
Waldschmidt, D.
Merle, P.
Granito, A.
Huang, Y-H
Bodoky, G.
Yokosuka, O.
Rosmorduc, O.
Breder, V. V.
Gerolami, R.
Masi, G.
Ross, P. J.
Qin, S.
Song, T.
Bronowicki, J-P
Ollivier-Hourmand, I
Kudo, M.
Xu, L.
Baumhauer, A.
Meinhardt, G.
Han, G.
Bruix, J.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 281 - 281
[10] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Palmer, Daniel H.
Ma, Yuk Ting
Peck-Radosavljevic, Markus
Ross, Paul J.
Graham, Janet Shirley
Fartoux, Laetitia
Deptala, Andrzej
Wenz, Arne
Hocke, Julia
Loembe, Arsene-Bienvenu
Meyer, Tim
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 4 5 →